Unlocking the Potential of EFCAB9 as a Drug Target or Biomarker
Unlocking the Potential of EFCAB9 as a Drug Target or Biomarker
The protein encoded by theEF-hand calcium-binding domain-containing protein 9 (EFCAB9) is a member of the EF-hand family, a subgroup of the superfamily of protein tyrosine kinases (PTKs). EFCAB9 is highly conserved across various species, including humans, and its unique calcium-binding domain has been implicated in various physiological processes, including cell signaling, muscle contractions, and neurotransmitter release.
The EFCAB9 gene has been extensively studied, and several studies have identified its potential as a drug target or biomarker. In this article, we will delve into the current research on EFCAB9, highlighting its potential as a drug target and its potential as a biomarker for various diseases.
EFCAB9 as a Drug Target
EFCAB9 has been validated as a potential drug target due to its unique calcium-binding domain. This domain is known to modulate the activity of various protein tyrosine kinases, including PDGFR-尾, which is a key regulator of cell proliferation and survival. PDGFR-尾 signaling is highly activated in cancer cells, and thus, targeting EFCAB9 directly may offer therapeutic benefits for cancer treatment.
Several studies have shown that inhibition of EFCAB9 can lead to a reduction in the activity of PDGFR-尾 and its downstream targets, such as P-CAF, T-p73, and S-p300. These results suggest that targeting EFCAB9 may be an effective way to inhibit the growth and survival of cancer cells.
In addition to its potential as a cancer therapeutic, EFCAB9 may also be a useful drug target for treating other conditions that involve excessive activation of PDGFR-尾 signaling. For example, EFCAB9 has been shown to play a role in the regulation of neural development and plasticity, and alterations in its expression have been implicated in various neurological and psychiatric disorders.
EFCAB9 as a Biomarker
EFCAB9 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique calcium-binding domain has been shown to interact with several protein tyrosine kinases, including PDGFR-尾, which is a known indicator of cancer and neurodegenerative diseases.
Studies have shown that increased expression of EFCAB9 is associated with poor prognosis in various disease models, including cancer and neurodegenerative diseases. Additionally, decreased expression of EFCAB9 has been shown to improve survival in cancer and neurodegenerative disease models.
In addition to its potential as a biomarker, EFCAB9 may also be a useful target for diagnostic tools in various diseases. For example, its unique calcium-binding domain has been shown to interact with several proteins, including calbindin, which is a well-established biomarker for cancer. By modulating the activity of EFCAB9, researchers may be able to develop new diagnostic tests for cancer, including non-invasive tests that are less invasive than traditional imaging techniques.
Conclusion
In conclusion, EFCAB9 is a highly conserved protein that has been extensively studied for its potential as a drug target and biomarker. Its unique calcium-binding domain has been shown to modulate the activity of various protein tyrosine kinases, including PDGFR-尾, which is a key regulator of cell proliferation and survival. Further research is needed to fully understand the mechanisms by which EFCAB9 interacts with its downstream targets and to develop new therapeutic strategies for cancer and other diseases.
Protein Name: EF-hand Calcium Binding Domain 9
Functions: Auxiliary component of the CatSper complex, a complex involved in sperm cell hyperactivation. pH-dependent Ca(2+) sensor required to activate the CatSper channel. Sperm cell hyperactivation is needed for sperm motility which is essential late in the preparation of sperm for fertilization. Associates with the CatSper complex via direct interaction with CATSPERZ, and senses intracellular Ca(2+). Together with CATSPERZ, associates with the CatSper channel pore and is required for the two-row structure of each single CatSper channel
More Common Targets
EFCC1 | EFEMP1 | EFEMP2 | EFHB | EFHC1 | EFHC2 | EFHD1 | EFHD2 | EFL1 | EFL1P1 | EFNA1 | EFNA2 | EFNA3 | EFNA4 | EFNA5 | EFNB1 | EFNB2 | EFNB3 | EFR3A | EFR3B | EFS | EFTUD2 | EGF | EGFEM1P | EGFL6 | EGFL7 | EGFL8 | EGFLAM | EGFR | EGFR-AS1 | EGLN1 | EGLN2 | EGLN3 | EGOT | EGR1 | EGR2 | EGR3 | EGR4 | EHBP1 | EHBP1-AS1 | EHBP1L1 | EHD1 | EHD2 | EHD3 | EHD4 | EHF | EHHADH | EHMT1 | EHMT1 intronic transcript 1 | EHMT2 | EI24 | EI24P2 | EID1 | EID2 | EID2B | EID3 | EIF1 | EIF1AD | EIF1AX | EIF1AX-AS1 | EIF1AXP1 | EIF1AY | EIF1B | EIF1B-AS1 | EIF1P3 | EIF2 complex | EIF2A | EIF2AK1 | EIF2AK2 | EIF2AK3 | EIF2AK3-DT | EIF2AK4 | EIF2B1 | EIF2B2 | EIF2B3 | EIF2B4 | EIF2B5 | EIF2D | EIF2S1 | EIF2S2 | EIF2S2P3 | EIF2S2P4 | EIF2S3 | EIF3A | EIF3B | EIF3C | EIF3CL | EIF3D | EIF3E | EIF3EP1 | EIF3EP2 | EIF3F | EIF3FP2 | EIF3FP3 | EIF3G | EIF3H | EIF3I | EIF3IP1 | EIF3J | EIF3J-DT